论文部分内容阅读
目的观察奥扎格雷钠对急性脑梗死(ACI)患者血清C反应蛋白(CRP)含量与疗效的影响。方法 136例急性脑梗死患者随机分为观察组和对照组各68例,对照组采用脑梗死常规治疗,观察组在常规治疗基础上加用奥扎格雷钠治疗,治疗前及14d后测定CRP水平变化,并对神经功能缺损进行标准评分。结果治疗后14d观察组CRP水平较对照组降低,差异有统计学意义(P<0.05),观察组神经功能缺损评分低于对照组,差异有统计学意义(P<0.05)。结论奥扎格雷钠能降低ACI患者血清CRP水平,有利于减轻炎症反应,提高临床疗效。
Objective To observe the effect of ozagrel sodium on serum C-reactive protein (CRP) level and therapeutic effect in patients with acute cerebral infarction (ACI). Methods One hundred and sixty-six patients with acute cerebral infarction were randomly divided into observation group (68 cases) and control group (68 cases). The control group was treated with conventional cerebral infarction. The observation group was treated with ozagrel sodium on the basis of routine treatment. CRP level Changes, and the standard score of neurological deficit. Results The level of CRP in the observation group decreased significantly 14d after treatment (P <0.05), and the score of neurological deficit in the observation group was lower than that of the control group (P <0.05). Conclusion Ozagrel sodium can reduce serum CRP levels in patients with ACI, is helpful to reduce the inflammatory response and improve clinical efficacy.